Overactive Bladder Treatment Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions and By Key Players: KYORIN Pharmaceutical, Allergan, Astellas Pharma Inc., Laborie

The Overactive Bladder Treatment market is estimated to grow at a CAGR of 3.9% over the forecast period, from USD 4,803.20 million in 2021 to USD 5,459.14 million by 2027.

Overactive Bladder Treatment Market Overview

The rise in the prevalence of kidney-related disorders, the increased focus on research and development capabilities in medical devices and the adoption of modern IT healthcare technologies, the growing elderly population base around the world, and rising investment for the development of healthcare infrastructure, particularly in developing economies, are all contributing to the expansion of the overactive bladder treatment market.

The increased prevalence of disorders such as Parkinson's disease, which causes overactive bladder problem, and an ageing population are the key drivers of the global market. According to a United Nations (UN) report, there were a projected 727 million people aged 65 and up in the world in 2020. By 2050, this figure is expected to have more than doubled, reaching over 1.5 billion people. Urinary incontinence is more common as people get older. Overactive bladder has a significant detrimental impact on the elderly population's quality of life and health. With the rising prevalence of overactive bladder and other urinary illnesses, the overactive bladder therapy market is expected to rise rapidly. Other considerations include the introduction of novel intravenous treatments and aggressive marketing.

Industry News and Updates

December 23, 2020: Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)--

Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. This approval marks the first new oral branded OAB medication approved by the FDA since 2012, and it is the first product approval for Urovant Sciences.

April 27, 2021: Medtronic Receives FDA Approval to Launch Clinical Study for Implantable Tibial Neuromodulation Therapy for Bladder Incontinence--

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced approval from the U.S. Food and Drug Administration (FDA) to proceed with an investigational device exemption (IDE) trial to evaluate its internally developed implantable tibial neuromodulation (TNM) device — a therapy designed to provide relief from symptoms of bladder incontinence. The TITAN 1 Feasibility Study is a prospective, multicenter, feasibility study to characterize the procedure for the implantable TNM device in subjects with bladder incontinence.

What are the major Applications, Types and Regions for Overactive Bladder Treatment Market?

Market is segmented based on the type, applications, companies and regions.

By Type, it is segmented into

• Drugs


• Device

By Application, it is segmented into

• Idiopathic Overactive Bladder


• Neurogenic Overactive Bladder

Overactive Bladder Treatment Market Regional Analysis

North America is likely to lead the market for overactive bladder treatment. This is due to the fact that it has a well-established healthcare industry. The market is likely to increase over the forecast period, thanks to reimbursement for overactive bladder therapy, rising prevalence of the condition as people become older, and the existence of large competitors. According to the Rural Health in 2020, there are more than 46 million older persons in the United States, with that figure predicted to rise to about 90 million by 2050. With an increasing number of the vulnerable ageing population on the edge of acquiring overactive bladder condition, the demand for treatment is predicted to rise, boosting market growth. According to the National Association for Incontinence 2020, about 25 million adult Americans suffer with urine incontinence, with women accounting for 75-80% of the cases. The surge in demand for effective treatment is being fueled by the rising prevalence of urine incontinence, which leads to overactive bladder problems. The increased prevalence of bladder overactivity, the senior population, healthcare spending, and awareness regarding overactive bladder therapies are all pushing the market in this region.

• North America
  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East & Africa
  
  
  • Latin America
  
  
  
  

The Overactive Bladder Treatment Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Overactive Bladder Treatment Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

What is our Overactive Bladder Treatment Market report scope?

Frequently Asked Questions

What is the growth rate of Overactive Bladder Treatment Market?

The Overactive Bladder Treatment Market is growing at a CAGR of 3.9% over the next 5 years.

Who are the key players in Overactive Bladder Treatment Market?

KYORIN Pharmaceutical, Allergan, Astellas Pharma Inc., Laborie, Endo International PLC, Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson Services, Inc., Medtronic, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd, Macleods Pharmaceuticals Ltd, Urovant Sciences, Uro Medical

What are the significant types of Overactive Bladder Treatment Market?

Drugs, Device

What are the major end-use applications of Overactive Bladder Treatment Market?

Idiopathic Overactive Bladder, Neurogenic Overactive Bladder

All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.